New marker may predict pancreatic tumor aggressiveness
NCT ID NCT06406387
First seen Jan 15, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study is for 100 adults with non-functional pancreatic neuroendocrine tumors (NF-pNETs). Researchers want to see if two markers, called ATRX and DAXX, found in biopsy samples taken during an endoscopic ultrasound, can help predict how aggressive the tumor is. The goal is to improve current grading methods and better guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Verona
Verona, Italy
Conditions
Explore the condition pages connected to this study.